scispace - formally typeset
F

Francesco M. Marincola

Researcher at National Institutes of Health

Publications -  473
Citations -  41473

Francesco M. Marincola is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 94, co-authored 462 publications receiving 38129 citations. Previous affiliations of Francesco M. Marincola include Society for Immunotherapy of Cancer & Virginia Commonwealth University.

Papers
More filters
Book ChapterDOI

Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy

TL;DR: Molecular biomarkers derived from genomic and genetic studies are focused on to summarize the recent advances in the understanding of the mechanisms associated with distinct outcomes in the context of cancer immunotherapy.
Journal ArticleDOI

Current strategies employed in the manipulation of gene expression for clinical purposes

TL;DR: A review of different molecular tools that can be used to regulate gene expression and discuss their potential for clinical applications can be found in this article , where the authors also illustrate the different types of payloads that can also be used, and discuss recent developments in viral and non-viral vector technology.
Book ChapterDOI

Analysis of vaccine-induced T cells in humans with cancer.

TL;DR: Although tumor regression was not observed following active immunization in vivo, ex vivo assays evaluating TAA-specific T cells demonstrated tumor recognition and subsequent T-cell activation suggesting that tumor-specificT-cell induction indeed occurs but alone is not adequate to induce tumor regression.
Journal ArticleDOI

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Davide Bedognetti, +55 more
TL;DR: Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.
Journal ArticleDOI

Overview of melanoma vaccines and promising approaches.

TL;DR: It is difficult to envision anything better than melanoma vaccines to exemplify the effectiveness of modern biotechnology in developing biologically rational therapeutics.